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ABSTRACT: The hedgehog (Hh) pathway plays a central role in the development and
repair of our bodies. Therefore, dysregulation of the Hh pathway is responsible for many
developmental diseases and cancers. Basal cell carcinoma and medulloblastoma have well-
established links to the Hh pathway, as well as many other cancers with Hh-dysregulated
subtypes. A smoothened (SMO) receptor plays a central role in regulating the Hh signaling
in the cells. However, the complexities of the receptor structural mechanism of action and
other pathway members make it difficult to find Hh pathway inhibitors efficient in a wide
range. Recent crystal structure of SMO with cholesterol indicates that it may be a natural
ligand for SMO activation. Structural similarity of fluorinated corticosterone derivatives to
cholesterol motivated us to study the effect of dexamethasone, fludrocortisone, and
corticosterone on the Hh pathway activity. We identified an inhibitory effect of these three
drugs on the Hh pathway using a functional assay in NIH3T3 glioma response element cells.
Studies using BODIPY-cyclopamine and 20(S)-hydroxy cholesterol [20(S)-OHC] as
competitors for the transmembrane (TM) and extracellular cysteine-rich domain (CRD)
binding sites showed a non-competitive effect and suggested an alternative or allosteric binding site for the three drugs.
Furthermore, the three steroids showed an additive effect on Hh pathway inhibition when tested in combination with
cyclopamine. Our study reports the antagonistic effect of dexamethasone, fludrocortisone, and corticosterone on the Hh
pathway using functional assay and confirmed that they do not bind to the CRD or adjacent TM binding cavities of SMO. The
study also suggests that dexamethasone could be additionally beneficial as the adjuvant therapy for cancer patients with an
established link to the dysregulated Hh pathway.
■ INTRODUCTION
The hedgehog (Hh) pathway is an important pathway during
embryonic development, along with concurrently active ones,
such as Wnt or Notch pathways.1 Dysregulation of the Hh
pathway in humans is observed in several developmental
diseases and malformations and is found in many cancers.1,2
Approximately, one-fourth of all cancers either have a
dysregulated Hh pathway or are Hh-dependent for main-
tenance and growth.3 The Hh pathway includes several
elements.4 It is activated by Sonic Hedgehog (Shh) protein
that is autoprocessed into a shorter and cholesterol-modified
bioactive form of the protein (ShhN),5 that, in turn, binds to
the Patched (PTCH) receptor located in or near primary
cilium.6 This binding removes the inhibition of a smoothened
(SMO) receptor, a key regulator of the Hh pathway, and
induces translocation of the receptor to the plasma membrane
of primary cilium.7 The SMO activation leads to the
breakdown of the complex of SUFU and three glioma (Gli)-
associated transcriptional regulators.8 Gli activators move to
the nucleus to regulate transcription of various genes. Hh
signals induce cell proliferation through the upregulation of N-
Myc, cyclin D/E, and FOXM1. Disruption in pathway
regulation or feedback mechanisms is associated with the
development of cancers including but not limited to basal cell
carcinoma, medulloblastoma, and rhabdomyosarcoma.1,9 Re-
cent studies have suggested an important agonistic role of
cholesterol in Hh pathway regulation. The PTCH sequence is
evolutionarily conserved to bacterial transmembrane (TM)
transporters. PTCH was proposed to function as a pump for
small molecules (such as cholesterol), controlling the
activation of SMO.10 The binding of ShhN to PTCH causes
inhibition of cholesterol efflux and increases cholesterol
concentration inside the cell, which may be responsible for
the induction of SMO translocation from endosomes to the
plasma membrane.7 After translocation of SMO to the primary
cilium, an extracellular cysteine-rich domain (CRD) binding
site of SMO becomes exposed to its natural ligand. A crystal
structure of SMO bound to cholesterol suggested the CRD
binding site as the primary binding site for cholesterol.11
Corticosteroids and their therapeutic mimics are widely
prescribed drugs for many indications, including cancer,
because of their anti-inflammatory and immunosuppressive
properties.12 One of their targets is a glucocorticoid receptor
(GR) that can modulate the transcription of target genes by
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binding to specific elements of DNA, termed GR elements, and
subsequently interacting with the RNA polymerase II.13
Because of the discovery of cholesterol and other related
steroidal compound’s ability to modulate Hh pathway activity,
it is vital to study the contribution and mechanism of steroids
play in cancer therapy. Corticosteroids are the leading group
(comprising of hydrocortisone, prednisone, prednisolone,
dexamethasone, and many more) of steroids being used in
cancer therapy.14,15 They are prescribed to prevent allergic
reactions, control chemotherapy-induced nausea and vomiting,
increase appetite, reduce pain and swelling in the case of brain
cancer, reduce spinal cord compression, or to help in stem cell
transplantation.15 Recently, many steroids have been reported
to be SMO agonists along with cholesterol (also crystallized
with SMO).11,16,17 Fluorinated glucocorticoids such as
halcinonide and fluticasone were shown to bind to SMO and
activate the receptor.17 Because dexamethasone is widely used
in cancer therapy to decrease inflammation, swelling, or nausea
caused by chemotherapy,18,19 its activities against all essential
pathways including the Hh one may affect the net therapeutic
outcome.
These facts encouraged us to search for other corticosteroids
capable of inhibiting the Hh pathway and to explore the SMO
binding mode in order to choose a better steroid for
combination therapy for the management of Hh-dependent
cancers. With this aim, we tested dexamethasone and other
corticosteroids having a similar structure (fludrocortisone and
corticosterone); shown in Figure 1; for Hh pathway inhibitory
activity. The versatile and promising techniques to study
receptor−ligand interactions offer robust methods to test
various drugs in cell-based enzyme-dependent luminescence
methods20,21 or fluorescent bio-markers22 or metal-based
complexes23,24 for accurate quantification. We chose Gli-1-
dependent luciferase production21 and BODIPY-cyclop-
amine22 to test Hh pathway activity and SMO binding,
respectively. The cell-based assays confirmed the previously
reported results regarding dexamethasone and also showed for
the first time that fludrocortisone and corticosterone can also
inhibit the Hh pathway. The tested steroids failed to compete
with cyclopamine for known binding cavities in SMO,
indicating an allosteric mechanism for Hh pathway inhibition,
which further can be exploited to design a combination/
synergistic therapy for Hh-dependent cancers including SMO
inhibitors to reduce the side effects. Our study is the first
report to show fludrocortisone as an Hh pathway inhibitor.
Our report warrants more studies focused on steroids and
related compounds to find better alternatives for patients with
Hh-dependent cancers, immunomodulatory compounds with
additional beneficial effects and reduced adverse effects (such
as myopathy, neurotoxicity, etc.).
■ RESULTS
SMO is a seven-TM (7-TM) receptor that belongs to the
frizzled subfamily (class F) of the GPCR superfamily and plays
a vital role in the Hh pathway.25 The receptor has two primary
binding sites, one in the extracellular CRD region and another
in the TM region.4,25 Most SMO agonists and antagonists bind
to the TM binding site. The CRD binding site gained interest
recently when the crystal structure of SMO bound to
cholesterol was solved.11 Because of the similar structure of
fluorinated corticosteroids and cholesterol, we hypothesized
that they also affect the Hh pathway. Different experiments
were performed to validate this hypothesis.
Fluorinated Corticosteroids Inhibited Shh-Induced
Activation of the Hh Pathway. The three fluorinated
steroids selected, dexamethasone, fludrocortisone, and cortico-
sterone, were tested in a functional Hh pathway activity assay
using NIH3T3 Gli-RE cells stably expressing firefly luciferase
under the control of an 8× Gli response element (8× Gli-RE)
and treated with the active soluble form of Shh (further
referred to as ShhN). ShhN binding to PTCH induces SMO
translocation to PC and results in the activation of the Gli
transcription factors.21 This type of Gli reporter assay is robust
and was used to discover SAG, an SMO agonist.26 Cyclop-
amine was used as a control and was shown to inhibit the Hh
pathway in this functional assay many times.22 As expected,
cyclopamine showed inhibition of Gli-dependent increase in
luciferase because of the induction of the Hh pathway by
ShhN-conditioned media in NIH3T3 Gli RE cells. Similarly,
the compounds tested here also inhibited the functional Gli-
luciferase reporter to varying degrees (Figure 2a). Among the
tested compounds, dexamethasone and fludrocortisone
strongly inhibited the Gli-dependent luciferase production.
Also, there is evidence that the response to ShhN in NIH3T3
cells is an SMO-mediated pathway.27 Therefore, Figure 2a
shows that the steroids tested in this experiment inhibit Hh
pathway activity induced by ShhN.
In addition to ShhN, the SMO receptor and the Hh pathway
are also activated by cholesterol and various oxysterols (20(S)-
hydroxy cholesterol, OHC, being the most potential).28,29 To
further confirm the activity of fluorinated steroids under study,
we used 20(S)-OHC instead of ShhN-conditioned media as
the Hh pathway activator in Gli-luciferase assay. Cyclopamine
and tested compounds inhibit the 20(S)-OHC-induced Hh
pathway activity (Figure 2b). The Gli-inhibition mechanisms
for each of the fluorinated steroids needed to be further
studied.
To evaluate the concentration dependence of the Hh
inhibition, the NIH3T3 Gli-RE cells were treated with ShhN-
conditioned media (10%) with low-serum assay media and
serially diluted concentrations of cyclopamine, dexamethasone,
fludrocortisone, and corticosterone. The observed IC50 values
of cyclopamine, dexamethasone, fludrocortisone, and cortico-
sterone were 72.1, 7.11, 20.1 and 167 nM, respectively. The
concentration−response curves for all four compounds are
presented in Figure 3.
Fluorinated Corticosteroids Do Not Compete with
Cyclopamine or 20(S)-OHC for Their SMO Binding Sites.
Figure 1. Structures of cholesterol, 20(S)-hydroxycholesterol, cyclop-
amine, and corticosteroids studied.
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Cyclopamine directly binds to the 7-TM domain of SMO as
demonstrated by crystallography and biochemistry experi-
ments.11,30 By doing so, it is believed to influence the
activation-associated conformational changes in the receptor,
thus inhibiting the downstream Gli signaling. Competition
binding assays and functional assays were performed to check
the binding of test compounds to SMO at the cyclopamine 7-
TM binding site. The competition binding was evaluated in
HEK293t cells transiently transfected with mSMO, using
BODIPY-cyclopamine (at 5 nM conc.) as the fluorescent
probe. Cyclopamine showed a consistent concentration-
dependent decrease in fluorescence in the sample indicating
the displacement of BODIPY-cyclopamine from its binding
site with an IC50 of 342 nM. However, none of the tested
fluorinated steroids (i.e., dexamethasone, fludrocortisone, and
corticosterone) displaced BODIPY-cyclopamine (supple-
mented at 5 nM) from SMO in a dose-dependent manner
except for a minimal change in fluorescence at the highest
concentration of test compounds (50 μM). The results of the
competition binding assay are shown in Figure 4a. The results
indicated that the corticosteroids are likely to bind to a
different location than the cyclopamine-binding site of SMO.
To further explore the mechanism of inhibition of SMO by
corticosteroids, we tested them in a competitive functional
assay against 20(S)-OHC, a known small molecule agonist of
Figure 2. Effect of test compounds on Hh pathway activation. Hh pathway/SMO activation induced by ShhN-conditioned media results in
increased production of Gli-dependent luciferase. NIH3T3 Gli-RE cells stably transfected with 8× Gli-RE were used. (a) Inhibition of the Hh
pathway was tested by treating the cells with test compounds (10 μM) in the presence or absence of ShhN-conditioned media for 24 h in low-
serum conditions. (b) Inhibition of the Hh pathway was observed after treating the cells with test compounds (10 μM) in the presence of 20(S)-
OHC for 24 h in low-serum conditions. Data were acquired in triplicates from three independent experiments and are presented as the mean ± SD.
Abbreviations used in this figure: ShhNN-terminal of Shh protein, 20(S)-OHC20(S)-hydroxy cholesterol, CYCcyclopamine, DEX
dexamethasone, FDCfludrocortisone, and CRTcorticosterone.
Figure 3. Concentration response profile of SMO activation induced
by ShhN-conditioned media measured by the level of production of
Gli-dependent luciferase. NIH3T3 Gli-RE cells stably transfected with
8× Gli-RE were used. The cells were then treated with compounds
over a range of concentrations for 24 h in low-serum conditions. The
data were analyzed by nonlinear regression and sigmoid dose−
response using GraphPad Prism (GraphPad Software, Inc.). Data
were acquired in triplicates from three independent experiments and
are presented as the mean ± SD.
Figure 4. Fluorinated steroids do not bind to SMO cyclopamine binding sites. (a) BODIPY-cyclopamine competition binding assay was performed
with mSMO transiently transfected HEK293t cells. The geometric mean of fluorescence intensity of samples was estimated using flow cytometry in
the presence of different concentrations of cyclopamine (positive control, binds to the 7-TM binding site of SMO) and test compounds. (b) Gli-
luciferase functional assay was performed in NIH3T3 Gli-RE cells activated by a SMO agonist 20(S)-OHC (binds the CRD binding site of SMO).
The concentration−response curve of 20(S)-OHC was prepared in the presence of 0.5 μM concentration of steroids under study. The EC50 of
20(S)-OHC did not change instead max response decreased, indicating a noncompetitive relationship between the two tested compounds. Data
were acquired in triplicates from three independent experiments and are presented as the mean ± standard deviation (SD).
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SMO that binds to the CRD pocket.25 In NIH3T3 Gli-RE
cells, 20(S)-OHC causes a robust dose-dependent increase in
luminescence with an EC50 of 3.5 μM. When the cells were
exposed to 20(S)-OHC in the presence of dexamethasone,
fludrocortisone, and corticosterone at 0.5 μM concentration,
the maximum signaling response induced by 20(S)-OHC was
affected but its EC50 was not shifted indicating noncompetitive
inhibition (Figure 4b). The result indicates that the test drugs
do not bind to SMO at the 20(S)-OHC CRD binding site.
Cyclopamine and Fluorinated Corticosteroids Com-
bine To Inhibit Hh Pathway Activity. From the data
presented, it is clear that the tested corticosteroids (dexa-
methasone, fludrocortisone, and corticosterone) do not
compete for the CRD or TMD binding sites of SMO. We
hypothesized that the two compounds might synergize to
inhibit Hh pathway activity. We tested the combination using
fixed doses of cyclopamine and fluorinated corticosteroids at
100 nM concentration in NIH3T3 Gli-RE cells using
functional Gli-luciferase assay. The combination improves
Hh pathway inhibition as compared to individual compounds,
but this effect appears additive rather than synergistic. The
additive effect suggests that the two categories of compounds
tested here work through different sites to inhibit Gli
production in the cells, which leads to the inhibition of the
Hh pathway in cells. The additive inhibitory effect opens a
possibility of using these steroids in combination with other
Hh pathway inhibitors (e.g., vismodegib) to increase the anti-
Hh treatment efficacy. The results are presented in Figure 5.
The level of inhibition was maximal with dexamethasone and
minimal with corticosterone, which is in-line with the observed
IC50 of these compounds.
■ DISCUSSION
Corticosteroids have been used for brain cancer patients to
reduce tumor-associated edema and neurological deficits.18,31
When these widely used drugs15 are used in cancer,18 the
beneficial effects must be carefully evaluated and balanced
against numerous side effects, including osteoporosis and
cataract formation. Hh signaling pathway, mediated by SMO
and Gli proteins, is dysregulated in various cancers including
brain cancers.1,2,32,33 Recent reports on the inhibition of the
Hh pathway by steroids and steroid derivatives17,34 prompt
questions about the scope, scale, and direction of the Hh
modulation for each of the drugs in this class. Although several
steroids such as cholesterol,29 halcinonide, fluticasone,17 and
cholesterol derivative 20(S)-hydroxycholesterol35 are shown to
be SMO agonists, others are antagonists. The new SMO crystal
structure solved with cholesterol11 suggested that the steroids
could compete with cholesterol at the CRD binding site to
impair the Hh signaling. Most of the SMO antagonists (e.g.,
budesonide and ciclesonide) with a steroidal structure are
reported to be inhibitors of SMO-mediated ciliary trans-
location.34 Dexamethasone was reported to be the Hh pathway
inhibitor, but the mechanism of its inhibitory activity was not
fully described.17 Therefore, we wanted to test if dexametha-
sone and structurally similar steroids (fludrocortisone and
corticosterone) can also inhibit the SMO activity and whether
they compete with cyclopamine for the same binding site.
The experimental data reported here clearly shows that the
tested synthetic halogenated derivatives of cortisol, dexametha-
sone, and fludrocortisone are potential inhibitors of the Hh
pathway activity (Figures 2 and 3). The Gli-dependent
luciferase reporter assay performed in NIH3T3 Gli-RE cells
is a specific assay to see the effect of various molecules on Hh
pathway activity. However, these steroids were not binding to
SMO CRD and were not competing with cholesterol.
Furthermore, none of the tested steroids competed with
20(S)-OHC (SMO agonists binding to CRD cavity) in a
functional assay (Figure 4b). The BODIPY-cyclopamine
competitive binding assay (Figure 4a) illustrated that the
cyclopamine SMO-TM binding site is not affected either.
These results lead to a hypothesis that these compounds may
be affecting Hh pathway activity through an alternative SMO
binding site or an indirect mechanism. The experiment
showing an additive effect on inhibition of the Hh pathway
by cyclopamine (Figure 5) further supports this hypothesis.
A recent report29 shows that SMO activation can be
mediated by opening a tunnel through the TM part of the
receptor (from TM7 to the extracellular opening near CRD).
The authors proposed that cholesterol may travel through the
tunnel from intracellular to extracellular space of the cells, and
then binds to the CRD binding cavity to induce conforma-
tional change needed for SMO activation.29 This report
opened up the possibility of explaining the observed effect of
fluorinated corticosteroids characterized in our study. Dexa-
methasone and fludrocortisone may compete with cholesterol
(because of their structural similarity) and may inhibit the
travel of cholesterol through the tunnel such as structure
opened in the SMO TM region and allosterically inhibit SMO
activation. The tunnel binding may explain the lack of
competition with cyclopamine (7TM) or 20(S)-OHC (CRD).
Another plausible mechanism for Hh pathway inhibition by
steroids could involve effects on other related pathways. There
is evidence that the Hh pathway is influenced by other
pathways in the cells and responds to the changing cellular
microenvironment. The glucocorticoids (including dexametha-
sone) have been reported to decrease β-arrestin-2 gene
expression in human lung carcinoma cells in a concentration-
dependent manner.36 The Hh pathway inhibitory glucocorti-
coids may affect the pathway through several mechanisms
including but not limited to arrestin-dependent SMO local-
ization in primary cillia37 or SMO phosphorylation by G
protein-coupled receptor kinase 2 (GRK2).38 It was exper-
Figure 5. Fluorinated steroids (100 nM) and cyclopamine (100 nM)
additively inhibit Hh pathway activity. The Hh pathway activity
inhibition was tested by adding steroids (100 nM) with and without
cyclopamine (100 nM) in a functional assay using NIH3T3 Gli-RE
cells in the presence of ShhN-conditioned media. The two inhibitors
have an additive inhibition effect on the Hh pathway, indicating that
they act on different pathways resulting in reduced Gli production in
cells. Ctr = control, DEX = dexamethasone, FDC = fludrocortisone,
and CRT = corticosterone. Data were acquired in triplicates from
three independent experiments and are presented as the mean ± SD.
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imentally confirmed that before SMO activation, β-arrestin-2
interacts with Kif3a (a subunit of the kinesin-2 motor
complex) in cilia. The interaction between β-arrestin and
Kif3a is required for localization of SMO in primary cilia and
efficient Gli-dependent transcription.37,39 The β-arrestin-2 is
also associated with GRK2-mediated phosphorylation of the
SMO receptor cytoplasmic domains as demonstrated in HEK-
293 cells and zebrafish embryos.38,40 These findings highlight a
central role for the GRK-β-arrestin system in SMO signaling in
vertebrates. Therefore, it is possible that dexamethasone,
fludrocortisone, and corticosterone may exert their Hh
pathway inhibitory effects by binding to GR, which leads to
the inhibition of β-arrestin-2 gene expression. Glucocorticoids
may also affect the Hh pathway by changing the composition
of intracellular lipid rafts41 or binding to other possible
cholesterol binding sites.42,43
In conclusion, our report presents evidence that Hh/SMO
signaling can be efficiently inhibited by at least two steroids
which are often prescribed to cancer patients to reduce
chemotherapy-related and radiotherapy-related side effects and
brain edema. The binding mechanism is likely to be
complementary to the SMO inhibitor cyclopamine. This
study reveals that dexamethasone and fludrocortisone could
be better choices for adjuvant therapy in cancer patients with
dysregulated Hh pathway.
■ MATERIALS AND METHODS
Chemicals and Reagents. Cyclopamine was purchased
from Cayman Chemical Company. BODIPY-cyclopamine was
purchased from Biovision. Dexamethasone, fludrocortisone,
and corticosterone were purchased from Sigma. 20(S)-hydroxy
cholesterol was purchased from Tocris Bioscience.
For the assays, test compounds were prepared at 10-fold the
final well concentrations in assay media, across six concen-
trations, using 1:10 or 1:5 serial dilutions from the highest
concentration (stock solution conc. usually 10 mM). All stock
solutions were stored at −20 °C.
Cells and Plasmids. HEK293t cells were obtained from
ATCC. NIH3T3 Gli-RE cells (NIH3T3, mouse embryonic
fibroblast cells, stably transfected with firefly luciferase under
the transcriptional control of 8× Gli response element) were
obtained from BPS Bioscience, San Diego, CA. HEK293t cells
were cultured in the Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% of fetal bovine serum (FBS)
at 37 °C in an atmosphere with 5% CO2. NIH3T3 Gli-RE cells
were cultured in the DMEM supplemented with 10% of BCS
and Geneticin.
The mSMO and ShhN (Shh N-terminal domain) plasmids
were purchased from Addgene. All vectors were propagated in
XL10 Gold competent cells, purified with NucleoBond Xtra
Midi kit (Clontech), and sequenced (Genewiz).
For the production of ShhN-conditioned media and for the
BODIPY-cyclopamine competition binding assay, HEK293t
cells were seeded at a density of 1.5 × 106 in a 6 cm dish,
allowed to grow overnight, and then transfected with either
ShhN or mSMO plasmid DNA (6 μg DNA per 6 cm dish)
using a TransIT transfection reagent (Mirus Bio LLC)
according to the manufacturer’s instructions. Cell culture
media was replaced with DMEM + 10% FBS before mSMO
transfection and with DMEM + 10% BCS before ShhN
transfection. The transfected dish was incubated for approx-
imately 24 h at 37 °C. The ShhN-conditioned medium was
produced in ShhN-transfected HEK293t cells. The culture
medium from ShhN-transfected HEK293t cells was collected
and aliquoted in single-use 1.5 mL Eppendorf tubes. This
ShhN-enriched media was either used fresh or stored at −20
°C for later use. For BODIPY-cyclopamine competition
binding assay, HEK293t cells transfected with mSMO plasmid
were lifted with trypsin (0.25%), re-plated in 96-well adherent
plates, and incubated for an additional 24 h before the
experiment.
Gli-Luciferase Functional Assay. NIH3T3 Gli-RE cells
were plated at 1.2 × 104 cells per well in 100 μL of DMEM +
10% BCS media in 96-well tissue culture-treated plate (Falcon,
353219). After 24 h, when the cells reached confluency, the
culture medium was replaced with 80 μL/well of the assay
medium [Optimem ± 10 mM (4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid ± 1 mM sodium pyruvate + 1×MEM
NEAA]. Serial dilutions of test compounds (10× of final
concentrations) were prepared in assay media. 10 μL of diluted
compounds (10× the final concentration) or control media
were added to the plate after which the plate was incubated for
15−30 min at 37 °C. Then, the cells were stimulated by the
addition of either ShhN-conditioned media or control media
(DMEM ± 10% BCS) at a final concentration of 10% (1%
BCS per well). Following incubation of the plate for at least 28
h at 37 °C, the cells were simultaneously lysed and
supplemented with a luciferase substrate by the addition of
an equal volume of Steady-Glo reagent (Promega, E2520)
directly to the assay media. Plates were mixed by pipetting,
centrifuged to eliminate foam, incubated for 10 min, and
analyzed using a Perkin Elmer Victor X luminescence plate
reader. The results were analyzed using nonlinear regression
(Prism 6, GraphPad Software, La Jolla, CA). Data were
normalized to the maximal response observed for ShhN-
stimulated cells in the same experiment. A sigmoidal-dose
response curve was used as a model for data analysis and IC50
value calculation.
BODIPY-Cyclopamine Competition Binding Assay.
HEK293t cells transiently transfected with mSMO were lifted
with trypsin (0.25%) and replated at 6 × 104 cells in 80 μL
DMEM + 10% FBS per well in a 96 well tissue culture-treated
plate (Falcon, 353219). The plate was incubated at 37 °C for
24 h. Serial dilutions of test compounds (10× final
concentrations) were prepared in culture media. 10 μL of
diluted compounds or control media were added to the plate
after which the plate was incubated at 37 °C for 10 min. Next,
BODIPY-cyclopamine was added to each well at a final
concentration of 5 nM, except for control wells that were left
unstained. Following at least 1.5 h incubation at 37 °C in 5%
CO2, cells were lifted by vigorous pipetting, transferred to
conical bottom 96-well plates, and centrifuged at 400g for 5
min at 4 °C. The supernatant was discarded, cells were
resuspended in 300 μL of PBS + 0.5% BSA (freshly prepared),
and the plate was analyzed with a Guava benchtop flow
cytometer. The results were interpreted with FlowJo software
(version v10.1). Dose−response curves were constructed in
Prism 6 (GraphPad Software, La Jolla, CA).
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